Comparative in vitro activities of rifamycin analogues against rifampin-sensitive and rifampin-resistant Mycobacterium tuberculosis

International Journal of Antimicrobial Agents

Volumn 8, Issue 3, 1997, Pages 209-214

  Dhople, Arvind M ^a   Dhople, Anita A ^a   Ibanez, Maria A ^a  

^a Florida Institute of Technology   (United States)

Author keywords

KRM compounds; Mycobacterium tuberculosis; Rifabutin; Rifampin; T9

Indexed keywords

3 (4 CINAMYL 1 PIPERAZYNYLIMINOMETHYL)RIFAMYCIN SV; 3' HYDROXY 5' (4 ISOPROPYL 1 PIPERAZINYL)BENZOXAZINORIFAMYCIN; KRM 2312; RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAMYCIN DERIVATIVE; RIFAMYCIN SV DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; DRUG POTENCY; GROWTH INHIBITION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RADIOMETRY;

EID: 0030916805     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(97)00016-2     Document Type: Article

References (26)

1. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 1991;72:1-6.
2. Sudre P, Ten Dam HG, Kochi A. Tuberculosis: a global overview of the situation today. Bull World Health Org 1992;70:149-159.
3. Slutkin G, Leowski J, Mann J. The effects of AIDS epidemic on the tuberculosis problem and tuberculosis programs. In: Fleming AF, Carbelo M, Fitzsimmons DW, Bailey MR, Mann J (eds) The Global Impact of AIDS. Alan R. Liss, New York, 1988, pp. 21-25.
4. Barnes PF, Bloch AB, Davidson PT, Snider DE. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 1991;24:1644-1650.
5. Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in developing countries:epidemiology and strategies for prevention. Tubercle Lung Dis 1992;73:311-321.
6. Steinberg JL, Nardell EA, Kass EH. Antibiotic prophylaxis after exposure to antibiotic-resistant Mycobacterium tuberculosis. Rev Infect Dis 1988;10:1208-1219.
7. Cynamon MH. Comparative in vitro activities of MDL 473, rifampin, and ansamycin against Mycobacterium intracellulare. Antimicrob Agents Chemother 1985;28:440-441.
8. Saito H, Sato K, Tomioka H. Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex. Tubercle 1988;69:187-192.
9. Heifets LB, Lindholm-Levy PJ, Flory M. Comparison of bacteriostatic and bactericidal activity of isoniazid and ethionamide against Mycobacterium avium and Mycobacterium tuberculosis. Am Rev Respir Dis 1991;143:268-270.
10. Heifets LB, Iseman MD, Cook JL, Lindholm-Levy PJ, Drupa I. Determination of in vitro susceptibility of Mycobacterium tuberculosis to cephalosporins by radiometric and conventional methods. Antimicrob Agents Chemother 1985;27:11-15.
11. Tarrand JJ, Groschel DH. Evaluation of the BACTEC radiometric method for detection of 1% resistant populations of Mycobacterium tuberculosis. J Clin Microbiol 1985;21:941-946.
12. Heifets LB, Lindholm-Levy PJ. Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against Mycobacterium avium complex. Tubercle 1987;68:267-276.
13. Rynearson TK, Shronts JS, Wolinski W. Rifampin: in vitro effect on atypical mycobacteria. Am Rev Respir Dis 1971;104:272-274.
14. Dickinson JM, Mitchison DA. Experimental models to explain the high sterilizing activity of rifampin the chemotherapy of tuberculosis. Am Rev Respir Dis 1981;123:367-371.
15. Bruna CD, Schoppacassi G, Ungheri D, Jabes D, Morvillo E, Sanfilippo A. LM 427, a new spiropiperidyl rifamycin; in vitro and in vivo studies. J Antibiot 1983;36:1502-1506.
16. Dhillon J, Michison DA. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and Mycobacterium tuberculosis and their penetration into mouse peritoneal macrophages. Am Rev Respir Dis 1992;145:212-214.
17. Heifets LB, Lindholm-Levy PJ, Iseman MD. Rifabutin: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis. Am Rev Respir Dis 1988;137:719-721.
18. Dhople AM, Ibanez MA. The in vitro activities of novel benzoxazinorifamycins against Mycobacterium leprae. J Antimicrob Chemother 1995;35:463-471.
19. Dhople AM, Ibanez MA. In vivo activities of novel benzoxazinorifamycins against Mycobacterium leprae. Indian J Lepr 1995;67:375-382.
20. th International Congress of Chemotherapy. American Society for Microbiology, Washington, D.C., 1994, pp. 711-714.
21. 9). Antimicrob Agents Chemother 1995;39:2320-2324.
22. Dhople AM, Dimova V. In vitro activity of a new rifamycin derivative against Mycobacterium leprae. Arzneimittel-Forschung/Drug Res 1996;46:210-212.
23. Saito H, Tomioka H, Sato K, Emori M, Yamane T, Yamashita K, Hosoe K, Hidaka T. In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrob Agents Chemother 1991;35:542-547
24. Klemens SP, Grossi MA, Cynamon MH. Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1994;38:2245-2248.
25. Mor N, Simon B, Heifets LB. Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages. Antimicrob Agents Chemother 1996;40:1482-1485.
26. Tomioka H, Saito H, Sato t, Yamane K, Yamashita K, Hosoe K, Fujii K, Hidaka T. Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrob Agents Chemother 1992;36:387-393.